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CD59 on complement 
Abstract A soluble recombinant CD59#77 (rCD59#77), con- 
sisting of 77 amino acids starting from the N terminus of 
membrane-bound CD59, was prepared using a gene expression 
system in CHO cells. The rCD59#77 preparation was composed 
of glycosylated and non-glycosylated forms (G and NG forms). 
Unexpectedly, NG form was 7 times more potent than G form in 
complement inhibitory activity. Postulating that sialic acids on 
G-form molecules make it difficult for rCD59#77 to access 
nascent membrane attack complexes on the cell surface, the 
sialic acids were removed by neuraminidase treatment. However, 
the inhibitory activity was not changed. Next, one of two putative 
N-glycosylation sites was mutated by substituting Gin ts for 
Asn ts. The mutant, designated rCD59#77(N/Q), had no sugar 
moiety and was as active as the NG form of rCD59#77. These 
results suggest that the bulky sugar moiety at Asn js is not 
necessary for the complement-inhibitory activity of rCD59 and 
actually hampers that function. 
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I. Introduction 
CD59 is a membrane glycoprotein of 18-21 kDa which is 
anchored to the cell membrane via the glycosyl phosphatidyl 
inositol (GPI) moiety. It inhibits formation of the complement 
membrane attack complex (MAC), which injures or activates 
the host cells in inflammatory and autoimmune diseases [1,2]. 
CD59 interacts with both the C8 and C9 components of com- 
plement during MAC assembly on the cell surface, interfering 
with additional incorporation of C9 into the intermediate 
complex [3,4]. It was first isolated from erythrocyte membrane 
[5] and then found on various kinds of cells [6,7]. 
Patients with paroxysmal nocturnal hemoglobinuria (PNH) 
are deficient in CD59, and their erythrocytes are highly sus- 
ceptible to complement attack [8]. It has been shown that 
CD59 is essential for protection of not only erythrocytes but 
also nucleated cells against complement a tack [9,10]. Matsuo 
et al. recently found that a monoclonal antibody capable of 
inhibiting the activity of rat CD59 reduced tissue injury in rat 
complement-mediated experimental glomerulonephritis [11]. 
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In a clinical study, myocardial infarction decreased CD59 
molecules and caused MAC formation at the infarcted lesions 
[12]. 
We have cloned and sequenced human CD59 cDNA using 
mRNA from peripheral blood mononuclear cells [13]. It en- 
codes a polypeptide composed of 128 amino acids (a.a.) con- 
taining a signal sequence of 25 a.a. at the amino terminus and 
a signal sequence of 26 a.a. for GPI anchoring at the carboxyl 
terminus [13,14]. The mature molecule consists of 77 a.a. an- 
chored with GPI on the cell surface [14]. There are two puta- 
tive N-glycosylation sequences (Asn-X Ser/Thr) at a.a. posi- 
tions 8-10 and 18-20 of the mature molecule [15]. It was 
recently reported that urinary CD59 has fucosylated bianten- 
nary and triantennary oligosaccharide chains with variable 
sialylation, which is linked to Asn 18 [16]. 
Ninomiya et al. [17] used N-glycanase to remove the N- 
linked sugar moiety from human CD59 purified from erythro- 
cytes and found that the deglycosylated CD59 was one-tenth 
as active as the original molecule in inhibiting MAC forma- 
tion. In addition, CHO cells transfected with cDNA of human 
CD59 were cultured in the presence of 1-deoxymannojirimy- 
cin, which inhibited conversion from high-mannose to com- 
plex glycoproteins, made the cells more susceptible to injury 
by complement [17]. In contrast o these findings, it was re- 
cently reported that mouse fibloblast ransfectants expressing 
a mutant CD59 lacking the sugar chain were more resistant to 
complement a tack than transfectants expressing the wild-type 
CD59 [18]. Thus, the significance of the sugar chain remains 
to be elucidated in connection with the functional properties 
of CD59. 
In this study, we prepared human rCD59#77 and a mutant 
rCD59#77(N/Q) lacking a sugar chain by using a CHO cell 
expression system and elucidated the significance of the sugar 
chain in the complement-inhibitory function. Our results ug- 
gested that the bulky sugar at Asn is hampers CD59 function. 
2. Materials and methods 
2.1. Assay of inhibition of reactive hemolysis 
Human factors B and D were kindly provided by Dr. Y. Nakano, 
Showa University (Tokyo, Japan). Cobra venom factor (CVF) and 
human complement components C5 and C6 were purchased from 
Quidel (San Diego, CA). C5b6 complex was prepared by the method 
described previously [19], with a minor modification. Briefly, 2.5 ~g of 
CVF, 10 ~g of factor 13 and 10 I.tg of factor D were mixed in 40 ~tl of 
phosphate-buffered saline (PBS) containing 50 mM MgCI~. The mix- 
ture was incubated at 37°C for 15 min to form CVF-Bb complexes, 
and then allowed to react with 100 ~tg of C5 and 100 Ixg of C6 in 240 
/al of PBS at 37°C for 15 h. The C5b6 complex thus prepared was 
stored at -80°C until use. A hemolysis assay mixture contained 25 lal 
of 1 × 109/ml guinea pig erythrocytes (Egp), 25 ~1 of 2.5% human 
serum, 25 ~tl of CD59 solution and 25 ~tl of the C5b6 complex diluted 
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320-fold in a total of 100 gl of 25 mM veronal buffer (pH 7.4) con- 
taining 146 mM NaCI, 10 mM EDTA and 0.1% gelatin (EDTA- 
GVB). After incubation at 37°C for 30 min and centrifugation, the 
optical density of the supernatant was measured at 414 nm. The 
percentage of hemolysis was calculated relative to the control. Com- 
plement inhibitory activities were expressed as the percentages of re- 
(! uction in hemolysis relative to that observed in the absence of CD59. 
. 2. cDNA constructs 
A plasmid of pEBD vector was constructed by insertion of an 
xpression unit of the dehydrofolate reductase (DHFR) gene as a 
...election marker into a unique AatlI site of pEF-BOS (kindly pro- 
, ided by Dr. S. Nagata, Osaka Bioscience Institute, Osaka, Japan 
_~0]). To construct a truncated CD59#77 cDNA lacking 26 a.a. resi- 
, ues in the carboxyl terminus, CD59#77 cDNA fragment was ampli- 
ed with Taq polymerase in the presence of oligonucleotides P1, 5'- 
"CTAGAGCGGCCGCTCCCCATCCGCTCAAGCAGGCCACCA- 
"GGGAATCCAAGGAGGGTCT-3' and P2, 5'-TCTAGACTC- 
~]AGCTATTAATTTTCAAGCTGTTCGTTAA-Y as probes and 
~GEM352-3, which had the full length of CD59 cDNA [13] as the 
emplate. After digestion with XbaI, the cDNA fragment was inserted 
nto the )(hal site of pEBD. 
To construct a plasmid, i.e., pCD59#77(N/Q), expressing 
CD59#77(N/Q), in which Gin is substituted for Asn is, a two-step 
)olymerase chain reaction (PCR) was carried out. An N-terminal half 
:DNA fragment containing Gln at position 18 was initially amplified 
~)y PCR with oligonucleotides N/Q and P1 as primers. Oligonucleo- 
ide N/Q, 5'-GAGACACGCGTCAAAATCAGATGAACATTG- 
3ACGGCTGTTTT-Y, which corresponds to a.a. positions 14 to 
~0, includes a Gln codon at the 18th a.a. and a restriction enzyme 
14luI recognition site. A C-terminal half cDNA fragment was also 
implified by PCR with oligonucleotides Mlu, 5'-TCTGATTTT- 
3ACGCGTGTCTCATTACCAAA-3', containing MluI site and P2 
ts probes. After cleavage with J(bal and MluI, both cDNA fragments 
~ere inserted into the XbaI site in pEBD to obtain pCD59#77(N/Q). 
?.3. Expression and purification of rCD59#77 and rCD59#77 (N/Q) 
For preparation of these protein molecules, CHO cells lacking the 
DHFR gene were transfected with the expression vectors described 
above with LipofectAMINE (Gibco BRL) according to the manufac- 
turer's protocol. At 72 h after transfection, the medium was changed 
from aMEM supplemented with 10% fetal calf serum to ribonucleo- 
side- and deoxyribonucleoside-free aMEM supplemented with 10% 
fetal bovine serum dialyzed against PBS. The transfectants were 
pooled and then selected in the same medium containing methotrex- 
ate, added in stepwise increments from 1 ~tM to 1 mM. The cells 
showing the highest expression were cloned by limiting dilution. The 
expression levels of rCD59#77 and rCD59#77(N/Q) were about 50 
mg/l and 20 mg/l, respectively. The culture supernatants were centri- 
fuged at 10000xg for 15 min, and the rCD59#77 and rCD59#77(N/ 
Q) proteins were purified with a monoclonal antibody against CD59 
as described previously [21]. 
2.4. Separation of G and NG forms of rCD59#77 
To separate the G and NG forms of rCD59#77, 1 mg of the 
rCD59#77 obtained as described above was dissolved 2 ml of 20 
mM Tris-HCl (pH 8.0) and applied to a DEAE-5PW column (Tosoh 
Co., Ltd., Tokyo, Japan). The bound proteins were eluted with a 
linear gradient of NaCI from 0 to 0.25 M in 20 mM Tris-HCl (pH 
8.0). The NG form was eluted at 0.08 M NaC1, while the G form was 
recovered in four fractions of 0.11, 0.13, 0.135 and 0.14 M NaC1. 
Since the complement-inhibitory activities of those four fractions 
were very close, they were combined and used as the G form in 
further experiments. 
2.5. Removal of sugar chains 
For removal of the N-linked sugar chain, 2 lag of rCD59#77 was 
heated at 95°C for 3 min in 15 mM sodium phosphate buffer (pH 7.5) 
containing 0.1% SDS, 10 mM 2-mercaptoethanol and 5 mM EDTA. 
After ccoling, 3 U of N-glycanase from Flavobacterium eningosep- 
ticum EC 3.5.1.52 (Genzyme Diagnostics, MA, USA) was added, and 
incubation was performed for 20 h at 37°C in the presence of 1% 
Nonidet P40 (NP40) and 0.3 mM PMSF. For digestion of sialic acids, 
30 lag of the purified G form of rCD59#77 was treated with 1 U of 
neuraminidase from Arthrobacter ureafaciens EC 3.2.1.18 (Sigma 
Chemical Co., MO, USA) at 37°C for 20 h in 80 mM sodium acetate 
buffer (pH 5.0) containing 1.6 mM CaClz and 0.3 mM PMSF. The G 
form thus treated was purified again by affinity chromatography with 
the monoclonal antibody against CD59. 
2.6. Other procedures 
Sodium dodecyl sulphate-polyacrylamide gel lectrophoresis (SDS- 
PAGE) was carried out with a 15-25% gradient gel under reducing 
conditions, and proteins were detected by silver staining. To calculate 
the isoelectric point (pI) values, rCD59 molecules were separated by 
electrophoresis in polyacrylamide gel containing ampholine (Pharma- 
cia Biotech, Uppsala, Sweden). The separated proteins were electro- 
blotted to a polyvinylidine difluoride (PVDF) membrane. The mem- 
brane with proteins was incubated with 1 ~tg/ml of biotinylated rabbit 
antibodies against human CD59 in 20 mM Tris-HC1 (pH 7.4) contain- 
ing 150 mM NaCI, 0.1% Tween 20 and 1% BSA, and then with 1 lag/ 
ml horse radish peroxidase-conjugated avidin (Amersham Interna- 
tional plc, Buckinghamshire, UK). The blot was developed by a chem- 
iluminescence method using an ECL kit (Amersham). The protein 
concentrations in the rCD59 preparations were measured with a 
Micro BCA protein assay kit (Pierce Chemical Co., Rockford, IL). 
3. Results and discussion 
3.1. Complement inhibitory activities of G and NG forms of 
rCD59#77 
Soluble rCD59#77 was prepared using a gene expression 
system in CHO cells and purified by affinity chromatography 
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Fig. 1. Separation of G and NG forms of rCD59#77 and their complement inhibitory activities. (A) rCD59#77s which were expressed in insect 
(lane 1) and CHO (lane 2) cells were affinity-purified with an anti-CD59 antibody. The purified rCD59#77 (CHO) was either treated with N- 
glycanase (lane 3) or loaded on a DEAE-5PW column to separate the NG form (lane 4) and G form (lane 5). They were analyzed by SDS- 
PAGE and silver staining. The asterisk indicates N-glycanase (34.6 kDa). (B) The complement-inhibitory activities of these rCD59#77s were as- 
sessed in a reactive hemolysis ystem. The rCD59#77 expressed in insect (O) or CHO (O) cells, NG (• )  and G (I) forms. 
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Fig. 2. Treatment of G form with neuraminidase. (A) Isoelectric points. The purified G form of rCD59#77 was treated with neuraminidase 
and then analyzed by isoelectrofocusing. The proteins were transferred to a PVDF membrane and visualized by immunoblotting with rabbit 
anti-CD59 antibodies, rCD59#77 produced in insect cells (lane 1), CHO cells (lane 2), NG form (lane 3), G form (lane 4) and G form treated 
with neuraminidase (lane 5). (B) Molecular weights determined by SDS-PAGE. NG form (lane 1), G form (lane 2) and G form treated with 
neuraminidase (lane 3). (C) Complement-inhibitory activities of NG form (•),  G form (111) and neuraminidase-treated G form (o) in reactive 
hemolysis. 
with an antibody against CD59. The rCD59#77 preparation 
was analyzed by SDS-PAGE (Fig. 1A). At least seven protein 
bands were observed, ranging from 7 to 18 kDa. The smallest 
protein migrated at the position of 7 kDa, like the smallest 
protein expressed in the baculovirus expression system [21]. 
Some proteins produced in CHO cells were larger than the 
proteins produced by insect cells. Treatment of rCD59#77 
with N-glycanase resulted in disappearance of the molecules 
from 14 to 18 kDa and an increase in the amount of the 
smallest molecule (Fig. 1A, lane 3). In addition, these protein 
bands, except he 7 kDa one, were detected as glycoproteins 
by the periodate oxidation method (data not shown). These 
results imply that the molecules from 14 to 18 kDa are N- 
glycosylated proteins, while the 7 kDa molecule is a non-gly- 
cosylated one. The differences in the molecular weights seem 
to be due to heterogeneity in their N-linked sugar moiety. The 
relative amounts of the G and NG forms of rCD59#77 pro- 
duced by the CHO cells were estimated to be 4:1 from the 
densities of the protein bands on SDS-PAGE. It has been 
shown that CD59 purified from human erythrocytes was all 
N-glycosylated [17]. 
The G and NG forms of rCD59#77 were separated by 
anion exchange chromatography to determine their comple- 
ment inhibitory activities. These two forms were clearly sepa- 
rated from each other (Fig. 1A, lanes 4 and 5). The comple- 
ment inhibitory activities were assessed in reactive hemolysis 
of guinea pig erythrocytes with human C5b6 complexes and 
human serum as the source of C7, C8 and C9 (Fig. 1B). The 
concentrations required to inhibit hemolysis by 50% (ICs0) 
were 0.17 and 1.2 ~tM for the NG and G forms, respectively. 
Thus, rCD59#77 lacking the sugar chain was 7 times more 
potent than the major constituent, rCD59#77 having the su- 
gar chain, in inhibiting reactive hemolysis. In addition, an- 
other rCD59#77 preparation produced by the baculovirus 
expression system was as potent as the NG form produced 
by the CHO cells. 
Ninomiya et al. [17] reported that the complement-inhibi- 
tory activity of CD59 purified from human erythrocyte mem- 
branes decreased by 90% after N-glycanase treatment and that 
the CD59-transfected CHO cells reduced the resistance to 
complement attack after growth in the presence of the 1-de- 
oxymannojirimycin, which inhibits the conversion of high 
mannose-type to complex-type glycoproteins. Their findings 
were thus inconsistent with ours. In their experiments, CD59 
was treated with N-glycanase by incubation for 24 h at pH 8.5 
in the presence of 0.1% NP40. There is a possibility that CD59 
lacking the sugar moiety is unstable under these conditions, 
thus decreasing its activity. In addition, 1-deoxymannojirimy- 
cin affects not only CD59 but also all glycosylated proteins, 
and this broad effect may make the cells less resistant o 
complement attack. 
3.2. Effect of sialic acids on the activity of G form 
Since baculovirus rCD59#77 was as active as the NG form 
and was assumed to have a high mannose-type sugar chain, 
which does not contain sialic acids, we postulated that the 
sialic acids hinder the access of CD59 molecules to nascent 
MAC on the cell surface, which is abundant in sialic acids 
because of their electric repulsion. In fact, erythropoietin 
showed 3 times higher activity after removal of sialic acids 
from the sugar moiety [22]. Thus, the sialic acids on the sugar 
moiety of rCD59#77 were removed with neuraminidase to test 
our hypothesis. In isoelectric focusing, NG form and baculo- 
virus rCD59#77 showed an pl of 5.0, which is consistent with 
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~:ig. 3. A mutant molecule, rCD59#77(N/Q), and its complement-inhibitory activity. Mutated rCD59#77(N/Q), in which Gin was substituted 
!or Asn ~8, was expressed in CHO cells and purified by affinity column chromatography. (A) Molecular weights. The wild-type rCD59#77 (lane 
) and rCD59#77(N/Q) (lane 2). (B) Complement-inhibitory activities in reactive hemolysis, rCD59#77(N/Q) (©), NG form (A) and G form 
ill) of rCD59#77. 
'.he value calculated from the primary a.a. sequence (Fig. 2A). 
the pI values of rCD59#77 produced in CHO cells were more 
tcidic, ranging from 4.7 to 3.8. The desialylated G form of 
:CD59#77 showed a single band at pI 5.0, implying the com- 
T)lete removal of sialic acids from the rCD59#77 molecules. 
Fhe complement inhibitory activity of the desialylated G form 
.vas not increased and remained less potent than that of the 
X!G form (Fig. 2C). Therefore, the decreased activity of the G 
"orm is not attributable to the presence of sialic acids. 
The molecular weights of desialylated G form became only 
t little smaller than the original G form, ranging from 14 to 
17 kDa (Fig. 2B). The molecular weights of the sugar moiety 
~¢ere still as large as 7 to 10 kDa, while the peptide is as small 
~s 7 kDa. These data suggest hat the bulky sugar chains 
~terically hinder the interaction of rCD59#77 with C8 and C9. 
~.3. A mutant molecule, rCD59#77(NlQ,) which lacks the 
N-linked sugar 
To confirm that the sugar moiety of rCD59#77 decreases 
she complement inhibitory activity, a plasmid expressing 
rCD59#77(N/Q), in which Gln was substituted for Asn 18, 
was constructed. The rCD59#77(N/Q) protein was expressed 
by transfecting the plasmid into CHO cells, rCD59#77(N/Q) 
showed a single protein band of 7 kDa in SDS-PAGE (Fig. 
3A), indicating that the protein is not glycosylated at all. The 
complement inhibitory activity of rCD59#77(N/Q) was as 
high as that of the NG form, and its ICs0 was 0.20 ~tM 
(Fig. 3B). Furthermore, other non-glycosylated mutants, i.e., 
CD59#77(S/G) and rCD59#77(S/A), in which Ser 2° was 
changed to Gly or Ala, were also as potent as the NG form 
(data not shown). These results indicate that the N-linked 
sugar moiety at Asn 18 decreases the complement inhibitory 
activity of rCD59#77. The fact that the N-linked sugar is 
not necessary for the complement inhibitory activity and ac- 
tually hampers the access to nascent MAC on the cell surface 
is not restricted to soluble CD59#77: the same case seems to 
apply to membrane-bound CD59, as shown in a short com- 
munication [18] 
The results shown here were unexpected because in general 
sugar moieties are necessary for the full biological activitiy of 
glycoproteins. For instance, N-glycanase digestion resulted in 
loss of the biological activities of glucose transporter [23] and 
complement component C9 [24]. Urokinase plasminogen acti- 
vator receptor [25], which has homology with CD59 in the 
a.a. sequence, showed a decreased affinity for the ligand after 
the N-glycosylation sites were removed by mutation [25]. 
Recent studies on the three-dimensional structure of recom- 
binant truncated CD59 (Leu I to Ash 7°) and CD59 purified 
from urine have revealed that CD59 is disc-shaped with a 
diameter of 30 A and a height of 15 A and closely packed 
with five disulfide bonds [26,27]. On the basis of this structure, 
Fletcher et al. [26] suggested that its inhibitory activity in- 
volves two loops composed of the 7th to 14th and the 20th 
to 24th amino acid. In addition, a synthetic peptide consisting 
of Cys 19 to Cys 39 was as active as urinary CD59 in its inhibi- 
tion of reactive hemolysis [28]. These findings suggest that the 
20th to 24th amino acid loop seems to be important for com- 
plement-inhibitory activity. Since Asn ~s is close to the active 
site, it is highly likely that the bulky sugar moiety linked to 
Asn is hampers the interaction with C8 and C9. 
MAC formation plays an important role in the pathogen- 
esis of inflammatory diseases uch as ischemia and autoim- 
mune diseases [29,30]. CD59 prevents cells from complement 
attack by interacting with activated C8 and C9 on nascent 
MAC [1]. In human myocardial infarction, CD59 disappeared 
and MAC was concomitantly deposited at the infarcted le- 
sions [12]. In these pathogenic onditions, administration of 
soluble CD59 is anticipated to be effective for suppressing the 
MAC formation which accompanies inflammation. Our pres- 
ent findings suggest hat non-glycosylated CD59#77 is more 
effective than the glyeosylated protein. 
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